207 related articles for article (PubMed ID: 31326432)
1. Multiple viral proteins and immune response pathways act to generate robust long-term immunity in Sudan virus survivors.
Sobarzo A; Stonier SW; Radinsky O; Gelkop S; Kuehne AI; Edri A; Herbert AS; Fedida-Metula S; Lutwama JJ; Yavelsky V; Davis C; Porgador A; Dye JM; Lobel L
EBioMedicine; 2019 Aug; 46():215-226. PubMed ID: 31326432
[TBL] [Abstract][Full Text] [Related]
2. Immune memory to Sudan virus: comparison between two separate disease outbreaks.
Sobarzo A; Eskira Y; Herbert AS; Kuehne AI; Stonier SW; Ochayon DE; Fedida-Metula S; Balinandi S; Kislev Y; Tali N; Lewis EC; Lutwama JJ; Dye JM; Yavelsky V; Lobel L
Viruses; 2015 Jan; 7(1):37-51. PubMed ID: 25569078
[TBL] [Abstract][Full Text] [Related]
3. Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu).
Sobarzo A; Groseth A; Dolnik O; Becker S; Lutwama JJ; Perelman E; Yavelsky V; Muhammad M; Kuehne AI; Marks RS; Dye JM; Lobel L
J Infect Dis; 2013 Jul; 208(2):299-309. PubMed ID: 23585686
[TBL] [Abstract][Full Text] [Related]
4. Correspondence of Neutralizing Humoral Immunity and CD4 T Cell Responses in Long Recovered Sudan Virus Survivors.
Sobarzo A; Stonier SW; Herbert AS; Ochayon DE; Kuehne AI; Eskira Y; Fedida-Metula S; Tali N; Lewis EC; Egesa M; Cose S; Lutwama JJ; Yavelsky V; Dye JM; Lobel L
Viruses; 2016 May; 8(5):. PubMed ID: 27187443
[TBL] [Abstract][Full Text] [Related]
5. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
6. Profiling the native specific human humoral immune response to Sudan Ebola virus strain Gulu by chemiluminescence enzyme-linked immunosorbent assay.
Sobarzo A; Perelman E; Groseth A; Dolnik O; Becker S; Lutwama JJ; Dye JM; Yavelsky V; Lobel L; Marks RS
Clin Vaccine Immunol; 2012 Nov; 19(11):1844-52. PubMed ID: 22993411
[TBL] [Abstract][Full Text] [Related]
7. A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses.
Wu F; Zhang S; Zhang Y; Mo R; Yan F; Wang H; Wong G; Chi H; Wang T; Feng N; Gao Y; Xia X; Zhao Y; Yang S
Viruses; 2020 Jan; 12(1):. PubMed ID: 31947873
[TBL] [Abstract][Full Text] [Related]
8. Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors.
Bramble MS; Hoff N; Gilchuk P; Mukadi P; Lu K; Doshi RH; Steffen I; Nicholson BP; Lipson A; Vashist N; Sinai C; Spencer D; Olinger G; Wemakoy EO; Illunga BK; Pettitt J; Logue J; Marchand J; Varughese J; Bennett RS; Jahrling P; Cavet G; Serafini T; Ollmann Saphire E; Vilain E; Muyembe-Tamfum JJ; Hensely LE; Simmons G; Crowe JE; Rimoin AW
J Infect Dis; 2018 Nov; 218(12):1929-1936. PubMed ID: 30107445
[TBL] [Abstract][Full Text] [Related]
9. Analysis of CD8
Sakabe S; Sullivan BM; Hartnett JN; Robles-Sikisaka R; Gangavarapu K; Cubitt B; Ware BC; Kotliar D; Branco LM; Goba A; Momoh M; Sandi JD; Kanneh L; Grant DS; Garry RF; Andersen KG; de la Torre JC; Sabeti PC; Schieffelin JS; Oldstone MBA
Proc Natl Acad Sci U S A; 2018 Aug; 115(32):E7578-E7586. PubMed ID: 30038008
[TBL] [Abstract][Full Text] [Related]
10. Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind FcγRI.
Radinsky O; Edri A; Brusilovsky M; Fedida-Metula S; Sobarzo A; Gershoni-Yahalom O; Lutwama J; Dye J; Lobel L; Porgador A
Sci Rep; 2017 Jul; 7(1):6054. PubMed ID: 28729706
[TBL] [Abstract][Full Text] [Related]
11. A Novel Bacterium-Like Particle-Based Vaccine Displaying the SUDV Glycoprotein Induces Potent Humoral and Cellular Immune Responses in Mice.
Xu S; Jiao C; Jin H; Li W; Li E; Cao Z; Shi Z; Yan F; Zhang S; He H; Chi H; Feng N; Zhao Y; Gao Y; Yang S; Wang J; Wang H; Xia X
Viruses; 2019 Dec; 11(12):. PubMed ID: 31835785
[TBL] [Abstract][Full Text] [Related]
12. Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.
Gilchuk P; Guthals A; Bonissone SR; Shaw JB; Ilinykh PA; Huang K; Bombardi RG; Liang J; Grinyo A; Davidson E; Chen EC; Gunn BM; Alter G; Saphire EO; Doranz BJ; Bukreyev A; Zeitlin L; Castellana N; Crowe JE
Front Immunol; 2021; 12():706757. PubMed ID: 34335620
[TBL] [Abstract][Full Text] [Related]
13. Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses.
Natesan M; Jensen SM; Keasey SL; Kamata T; Kuehne AI; Stonier SW; Lutwama JJ; Lobel L; Dye JM; Ulrich RG
Clin Vaccine Immunol; 2016 Aug; 23(8):717-24. PubMed ID: 27335383
[TBL] [Abstract][Full Text] [Related]
14. Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge.
Chen G; Koellhoffer JF; Zak SE; Frei JC; Liu N; Long H; Ye W; Nagar K; Pan G; Chandran K; Dye JM; Sidhu SS; Lai JR
ACS Chem Biol; 2014 Oct; 9(10):2263-73. PubMed ID: 25140871
[TBL] [Abstract][Full Text] [Related]
15. Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors.
Paquin-Proulx D; Gunn BM; Alrubayyi A; Clark DV; Creegan M; Kim D; Kibuuka H; Millard M; Wakabi S; Eller LA; Michael NL; Schoepp RJ; Hepburn MJ; Hensley LE; Robb ML; Alter G; Eller MA
Front Immunol; 2021; 12():682120. PubMed ID: 34093585
[TBL] [Abstract][Full Text] [Related]
16. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study.
Thom R; Tipton T; Strecker T; Hall Y; Akoi Bore J; Maes P; Raymond Koundouno F; Fehling SK; Krähling V; Steeds K; Varghese A; Bailey G; Matheson M; Kouyate S; Coné M; Moussa Keita B; Kouyate S; Richard Ablam A; Laenen L; Vergote V; Guiver M; Timothy J; Atkinson B; Ottowell L; Richards KS; Bosworth A; Longet S; Mellors J; Pannetier D; Duraffour S; Muñoz-Fontela C; Sow O; Koivogui L; Newman E; Becker S; Sprecher A; Raoul H; Hiscox J; Henao-Restrepo AM; Sakoba K; Magassouba N; Günther S; Kader Konde M; Carroll MW
Lancet Infect Dis; 2021 Apr; 21(4):507-516. PubMed ID: 33065039
[TBL] [Abstract][Full Text] [Related]
18. Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for Detection of Antibodies to Zaire Ebola Virus.
Ayouba A; Touré A; Butel C; Keita AK; Binetruy F; Sow MS; Foulongne V; Delaporte E; Peeters M
J Clin Microbiol; 2017 Jan; 55(1):165-176. PubMed ID: 27795350
[TBL] [Abstract][Full Text] [Related]
19. Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection.
Rimoin AW; Lu K; Bramble MS; Steffen I; Doshi RH; Hoff NA; Mukadi P; Nicholson BP; Alfonso VH; Olinger G; Sinai C; Yamamoto LK; Ramirez CM; Okitolonda Wemakoy E; Kebela Illunga B; Pettitt J; Logue J; Bennett RS; Jahrling P; Heymann DL; Piot P; Muyembe-Tamfum JJ; Hensley LE; Simmons G
J Infect Dis; 2018 Jan; 217(2):223-231. PubMed ID: 29253164
[TBL] [Abstract][Full Text] [Related]
20. Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques.
Marzi A; Fletcher P; Feldmann F; Saturday G; Hanley PW; Feldmann H
Lancet Microbe; 2023 Mar; 4(3):e171-e178. PubMed ID: 36739878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
